- Home
- SOWG vs MRKR Comparison
SOWG vs MRKR Comparison
Compare SOWG & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOWG
- MRKR
- Stock Information
- Founded
- SOWG 2010
- MRKR N/A
- Country
- SOWG United States
- MRKR United States
- Employees
- SOWG N/A
- MRKR N/A
- Industry
- SOWG Packaged Foods
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- SOWG Consumer Staples
- MRKR Health Care
- Exchange
- SOWG Nasdaq
- MRKR Nasdaq
- Market Cap
- SOWG 10.1M
- MRKR 11.6M
- IPO Year
- SOWG N/A
- MRKR N/A
- Fundamental
- Price
- SOWG $0.62
- MRKR $0.94
- Analyst Decision
- SOWG
- MRKR Strong Buy
- Analyst Count
- SOWG 0
- MRKR 2
- Target Price
- SOWG N/A
- MRKR $10.25
- AVG Volume (30 Days)
- SOWG 471.3K
- MRKR 153.3K
- Earning Date
- SOWG 11-14-2025
- MRKR 11-14-2025
- Dividend Yield
- SOWG N/A
- MRKR N/A
- EPS Growth
- SOWG N/A
- MRKR N/A
- EPS
- SOWG N/A
- MRKR N/A
- Revenue
- SOWG $9,271,376.00
- MRKR $5,388,071.00
- Revenue This Year
- SOWG $6.81
- MRKR N/A
- Revenue Next Year
- SOWG N/A
- MRKR $9.06
- P/E Ratio
- SOWG N/A
- MRKR N/A
- Revenue Growth
- SOWG N/A
- MRKR 44.55
- 52 Week Low
- SOWG $0.51
- MRKR $0.81
- 52 Week High
- SOWG $10.50
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- SOWG 41.51
- MRKR 47.18
- Support Level
- SOWG $0.52
- MRKR $0.84
- Resistance Level
- SOWG $0.82
- MRKR $1.02
- Average True Range (ATR)
- SOWG 0.08
- MRKR 0.05
- MACD
- SOWG -0.02
- MRKR -0.00
- Stochastic Oscillator
- SOWG 27.64
- MRKR 49.33
About SOWG Sow Good Inc. Common Stock
Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.